For the treatment of the following infections in adults:
- Complicated urinary tract infection (cUTI), including pyelonephritis
- Complicated intra-abdominal infection (cIAI)
- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
The treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- Medicine name:
- meropenem/vaborbactam (Vaborem)
- SMC ID:
- Pharmaceutical company
- A Menarini Pharmaceuticals UK Ltd
- BNF chapter
- Submission type
- Publication due date:
- 12 October 2020
- Patient group submission deadline:
- 03 August 2020